Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Oxantel Embonate
1. 68813-55-8
2. Telopar
3. Oxantel (pamoate)
4. Oxantel Embonate
5. Oxantel Pamoate [usan]
6. Oxantel Pamoate (usan)
7. Upy1d732t0
8. Cp-14445-16
9. 68813-55-8 (pamoate)
10. Nsc-759296
11. Cp-14,445-16
12. (e)-m-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl)phenol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) (salt)
13. 2-naphthalenecarboxylic Acid, 4,4'-methylenebis[3-hydroxy-, Compd.with 3-[(1e)-2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl]phenol(1:1)other Ca Index Names:phenol, 3-[(1e)-2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl]-,4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (1:1) (salt)
14. Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (e)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt)
15. Oxanel Pamoate
16. (e)-3-(2-(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)vinyl)phenol 4,4'-methylenebis(3-hydroxy-2-naphthoate)
17. 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic Acid;3-[(e)-2-(1-methyl-5,6-dihydro-4h-pyrimidin-2-yl)ethenyl]phenol
18. Telopar (tn)
19. Unii-upy1d732t0
20. Hms2093l04
21. Einecs 272-332-6
22. Cp 14,445-16
23. Oxantel Pamoate [mi]
24. Schembl601272
25. Chebi:7821
26. Schembl17801965
27. Chebi:93155
28. Amy3614
29. Oxantel Embonate [mart.]
30. Oxantel Embonate [who-dd]
31. Pharmakon1600-01505982
32. Hy-b1344
33. Oxantel Pamoate, Analytical Standard
34. Nsc759296
35. S5722
36. Akos026749864
37. Ccg-213588
38. Cs-5877
39. Nsc 759296
40. Ncgc00263960-01
41. 4,4'-methylenebis(3-hydroxy-2-naphthoic) Acid, Compound With (e)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1)
42. 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic Acid,3-[(e)-2-(1-methyl-5,6-dihydro-4h-pyrimidin-2-yl)ethenyl]phenol
43. Bs-42477
44. Sbi-0206880.p001
45. D00806
46. Sr-05000001812
47. Sr-05000001812-1
48. Q27164876
49. Q27291192
50. 2-naphthalenecarboxylic Acid, 4,4'-methylenebis[3-hydroxy-, Compd.with 3-[(1e)-2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl]phenol(1:1)
51. 4-[(3-carboxy-2-hydroxy-1-naphthalenyl)methyl]-3-hydroxy-2-naphthalenecarboxylic Acid 3-[2-(1-methyl-5,6-dihydro-4h-pyrimidin-2-yl)ethenyl]phenol
| Molecular Weight | 604.6 g/mol |
|---|---|
| Molecular Formula | C36H32N2O7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 604.22095136 g/mol |
| Monoisotopic Mass | 604.22095136 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 854 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antinematodal Agents
Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)
API SUPPLIERS
Jai Radhe Sales is your partner for all your sourcing needs.
NDC Package Code : 52286-0026
Start Marketing Date : 2017-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Oxantel Pamoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxantel Pamoate, including repackagers and relabelers. The FDA regulates Oxantel Pamoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxantel Pamoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oxantel Pamoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oxantel Pamoate supplier is an individual or a company that provides Oxantel Pamoate active pharmaceutical ingredient (API) or Oxantel Pamoate finished formulations upon request. The Oxantel Pamoate suppliers may include Oxantel Pamoate API manufacturers, exporters, distributors and traders.
click here to find a list of Oxantel Pamoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oxantel Pamoate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Oxantel Pamoate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Oxantel Pamoate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Oxantel Pamoate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oxantel Pamoate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Oxantel Pamoate suppliers with NDC on PharmaCompass.
Oxantel Pamoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oxantel Pamoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxantel Pamoate GMP manufacturer or Oxantel Pamoate GMP API supplier for your needs.
A Oxantel Pamoate CoA (Certificate of Analysis) is a formal document that attests to Oxantel Pamoate's compliance with Oxantel Pamoate specifications and serves as a tool for batch-level quality control.
Oxantel Pamoate CoA mostly includes findings from lab analyses of a specific batch. For each Oxantel Pamoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oxantel Pamoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxantel Pamoate EP), Oxantel Pamoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxantel Pamoate USP).
LOOKING FOR A SUPPLIER?
